Who are Plexium's investors?

Plexium's investors include aMoon, CRV (Charles River Ventures), DCVC (Data Collective), M Ventures, Neotribe Ventures, Pivotal Life Sciences, SoftBank Vision Fund, TCG Crossover and 2 more.

How much funding has Plexium raised?

Plexium has disclosed $60.1M raised across 1 round.

Where is Plexium headquartered?

Plexium is headquartered in San Diego, US.

Plexium

San Diego, US · Founded 2018 · 33 employees on LinkedIn · 10 known investors

Find your way into Plexium

Paths you didn't know you had: your email and LinkedIn already hold routes to the Plexium team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.

AI & Machine Learning Biotech Deep Tech

Founders & leadership

Michael Martin, Ph.D.Chief Executive Officer, President

Jorge F. DiMartino Jorge F. DiMartino is a physician scientist with over 18 years of experience in oncology drug development, including strategic involvement in the early development of marketed cancer therapeutics such as vismodegib, venetoclax, and enasidenib. He is founder of Plexium, which develops targeted protein degradation therapies.

Michael Martin President, Chief Executive OfficerInvestor at Takeda Ventures

Stephen Mullennix Chief Financial OfficerHe previously served as Chief Financial Officer and Chief Operating Officer at public and private companies in life sciences, biotechnology, and infrastructure, with experience leading public financings, M&A, and international teams.

Board

Serge Messerlian Chief Executive OfficerOperating Partner, DCVC Bio at DCVC Bio

Cariad ChesterBoard director

Patrick Rivers Board directorPortfolio Manager at aMoon

Leon Chen Board directorPartner at The Column Group

Rob Hopfner BoardManaging Director at Pivotal Life Sciences

Gorjan HrustanovicBoard Member

Mike Grey Executive Chairman

Investors · 10

aMoonlisted by aMoonRa'anana

How we know: aMoon's portfolio page · Not right? Tell us

CRV (Charles River Ventures)listed by CRV (Charles River Ventures)Bay Area · $250K – $5M

How we know: CRV (Charles River Ventures)'s portfolio page · Not right? Tell us

DCVC (Data Collective)listed by DCVC (Data Collective)Palo Alto · $5M – $25M

How we know: a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

M Ventureslisted by M VenturesAmsterdam · $10.8M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Neotribe Ventureslisted by Neotribe VenturesMenlo Park · $250K – $2M

How we know: Neotribe Ventures's portfolio page · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Franciscovia Rob Hopfner · board

How we know: Pivotal Life Sciences's portfolio page · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us

SoftBank Vision Fundlisted by SoftBank Vision FundLondon

TCG Crossoverlisted by TCG CrossoverPalo Alto

How we know: board seat on SEC Form D · Not right? Tell us

The Column Grouplisted by The Column GroupSan Francisco · $30M

How we know: The Column Group's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Lux CapitalreportedNew York · $100K – $100M

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$60.1M disclosed across 1 round · 2025

▶$60.1MraisedAug 2025 · 20 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Serge MesserlianDirector
Cariad ChesterDirector
Patrick RiversDirector
Leon ChenDirector
Rob HopfnerDirector
Michael MartinExecutive Officer, Director
Michael GreyDirector
Stephen MullennixExecutive Officer
Gorjan HrustanovicDirector

Offering amount: $60.1M
Amount sold: $60.1M
First sale: Jul 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

5 people who came through Plexium went on to found or lead other companies.

Ian PeikonBoard MemberFounded Cajal Neuroscience +1 Swamy VijayanChief Executive Officer, CofounderFounded Omniome +1 Serge MesserlianDirectorFounded Creyon Yi ZhangVP of EngineeringFounded Zafrens Mike GreyExecutive ChairmanFounded Auspex Pharmaceuticals

Related companies · 1

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Plexium.

Frequently asked questions

What does Plexium do?: Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
Who are Plexium's investors?: Plexium's investors include aMoon, CRV (Charles River Ventures), DCVC (Data Collective), M Ventures, Neotribe Ventures, Pivotal Life Sciences, SoftBank Vision Fund, TCG Crossover and 2 more.
How much funding has Plexium raised?: Plexium has disclosed $60.1M raised across 1 round.
Where is Plexium headquartered?: Plexium is headquartered in San Diego, US.